மலேசியா மருந்து கட்டுப்பாடு அதிகாரம்: Live & Latest News Updates : Vimarsana.com

Duopharma slumps to 13-month low ahead of EGM

KUALA LUMPUR: Shares of Duopharma Biotech Bhd hit a near 13-month low of RM2.35 on Thursday ahead of its shareholders’ meeting the next day for the proposed bonus issue

CGS-CIMB Research retains Add for Duopharma, TP RM3.67

KUALA LUMPUR: CGS-CIMB Equities Research is retaining its Add call for Duopharma Biotech with an unchanged target price of RM3.67 due to the potential long-term earnings prospects from the development of vaccine manufacturing capabilities, which is a key rerating catalyst. It said on Monday it was keeping its forecasts intact for now pending the details or further developments in the supply agreement for the Sinopharm vaccine, which it thinks could be signed by end of the month. “We retain our Add call on the stock with an unchanged TP of RM3.67 based on a CY22F P/E of 28.8 times (+2 standard deviations from its five-year mean),” the research house said.

'Significantly shorter' review time for WHO-approved vaccines

Malaysian PM lays out four-step plan for post-Covid exit

Malaysia's daily vaccination rate surpassed 200,000 level for first time on June 15 — JKJAV

King: Vaccination the only exit strategy from Covid-19 pandemic

Two Shots Against Delta; England Stays Locked Down: Virus Update

PM Muhyiddin unveils Malaysia's post-pandemic exit plan

Astra's Antibody Fails Test; Sputnik Defeats Delta: Virus Update

U.S. Deaths Approach 600,000; Astra Cocktail Fails: Virus Update